Biotech Values

[DewDiligence]

The Awesome Addressable Market for Anticoagulants




Lovenox/LMWH (medium blue)
Unfractionated heparin (orange)
Warfarin and variants (navy blue)
Other injectable agents (light blue)
Other oral agents (beige)


This chart comes from Bayer’s JPM webcast, so it naturally
emphasizes the other oral category that includes the jewel
of Bayer’s pipeline, Rivaroxaban. Even this forecast of huge
uptake for new oral agents shows a substantial pie slice for
the other injectable category, which includes such candidates
as MNTA’s M118 and GTCB’s ATryn. In my opinion, the other
injectable category in 2016 will greatly exceed the $2.4B figure
in the chart because there are acute-care indications where
injectables will continue to have the edge over oral agents.